Nanoencapsulated Cannabidiol–Cannabigerol Using Eudragit L100: In Vitro and In Vivo Evidence in Murine Colitis Model
Drugs and Drug Candidates · 31.01.2026 · 5 (1) · 10
DOI: 10.3390/ddc5010010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 31.01.2026. Verfasst von K. Antonio Cárdenas-Noriega und 8 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanotecnología en Farmacia Verde Para Tratamiento Antineoplásico, postdoctoral scholarship.
Abstract (Originalsprache)
Background
Phytocannabinoids such as cannabidiol (CBD) and cannabigerol (CBG) have received increasing attention in the context of inflammatory and intestinal disorders. However, direct comparisons between their individual and combined effects, as well as the influence of delivery systems, remain limited.
Objectives
This study evaluated the biological effects of free and nanoencapsulated CBD and CBG, including a cannabinoid–Eudragit L100 formulation, in an in vitro TNBS-treated intestinal cell model and an in vivo murine model of TNBS-induced colitis.
Methods
Cytotoxicity and treatment-associated effects of CBD, CBG, their 1:1 combination, and a nanoencapsulated formulation were assessed in TNBS-exposed Caco-2 cells. In parallel, BALB/c mice with TNBS-induced colitis were evaluated for colonic damage and inflammatory markers.
Results
CBD and CBG individually showed dose-dependent effects in Caco-2 cells, while their combined administration produced a greater effect than either compound alone at higher concentrations. The nanoencapsulated formulation preserved cellular metabolic activity following TNBS exposure. In vivo, both free combined and nanoencapsulated cannabinoids were associated with reduced epithelial damage and inflammatory alterations.
Conclusions
Nanoencapsulation using Eudragit L100 modulated the biological effects of CBD and CBG in experimental models of TNBS-induced intestinal injury.
Förderung
- Nanotecnología en Farmacia Verde Para Tratamiento Antineoplásico
- postdoctoral scholarship
Zitieren
APA
Cárdenas-Noriega, K. A., Elizondo-Luévano, J. H., Chávez-Montes, A., Rodríguez-Tovar, L. E., Franco-Molina, M. A., Zárate-Triviño, D. G., Pérez-Hernández, R. A., Soto-Domínguez, A., & Castillo-Velázquez, U. (2026). Nanoencapsulated Cannabidiol–Cannabigerol Using Eudragit L100: In Vitro and In Vivo Evidence in Murine Colitis Model. Drugs and Drug Candidates, 5(1), 10. https://doi.org/10.3390/ddc5010010
Vancouver
Cárdenas-Noriega KA, Elizondo-Luévano JH, Chávez-Montes A, Rodríguez-Tovar LE, Franco-Molina MA, Zárate-Triviño DG, et al. Nanoencapsulated Cannabidiol–Cannabigerol Using Eudragit L100: In Vitro and In Vivo Evidence in Murine Colitis Model. Drugs and Drug Candidates. 2026;5(1):10. doi:10.3390/ddc5010010
BibTeX
@article{CrdenasNoriega2026,
author = {Cárdenas-Noriega, K. Antonio and Elizondo-Luévano, Joel H. and Chávez-Montes, Abelardo and Rodríguez-Tovar, Luis E. and Franco-Molina, Moisés A. and Zárate-Triviño, Diana G. and Pérez-Hernández, Raymundo A. and Soto-Domínguez, Adolfo and Castillo-Velázquez, Uziel},
title = {Nanoencapsulated Cannabidiol–Cannabigerol Using Eudragit L100: In Vitro and In Vivo Evidence in Murine Colitis Model},
journal = {Drugs and Drug Candidates},
year = {2026},
volume = {5},
number = {1},
pages = {10},
doi = {10.3390/ddc5010010}
}
EUVIMED